文献速递外周动脉疾病

免疫检查点抑制剂与癌症患者外周动脉疾病相关

Immune checkpoint inhibitors are associated with peripheral artery disease in cancer patients.
PubMed 文献 · J Vasc Surg · 2026-02-11

这项多中心回顾性队列研究基于TriNetX平台,纳入2005至2025年接受ICI或非ICI治疗的癌症患者,经倾向评分1:1匹配后各66,766例。结果显示ICI组5年无PAD生存率更低(73.6% vs 81.7%,P < .001),PAD风险升高(HR 1.59,95%CI 1.53-1.64),各ICI类别一致;在高危患者中PAD与LEA风险亦升高。

要点

  • 癌症患者接受ICI治疗与PAD风险升高相关(HR 1.59,95%CI 1.53-1.64)。
  • 合并高血压、高脂血症、糖尿病或吸烟史的高危患者PAD与LEA风险更高。
  • 各ICI类别均显示PAD风险升高,提示需对ICI治疗患者进行血管评估与监测。

核心结论

  • 在癌症成人中,ICI治疗似乎与PAD和LEA风险升高相关,尤其是有血管危险因素者。

研究设计与样本

  • 回顾性多中心队列研究,使用TriNetX Analytics平台识别2005至2025年接受ICI或非ICI治疗的癌症患者,倾向评分1:1匹配后ICI组与对照组各66,766例。

主要发现

  • 匹配队列5年无PAD生存率ICI组73.6% vs 对照组81.7%(P < .001)。
  • 多变量分析示ICI治疗与PAD风险升高相关(HR 1.59,95%CI 1.53-1.64),CLTI与LEA风险相似。
  • 各ICI类别PAD风险均升高:PD-1抑制剂HR 1.56(95%CI 1.47-1.55),PD-L1抑制剂HR 1.48(95%CI 1.36-1.61),CTLA-4抑制剂HR 1.58(95%CI 1.43-1.74)。
  • 高危患者(n = 27,932)ICI组5年无PAD生存率70.3% vs 80.2%(P < .001),PAD风险HR 1.64(95%CI 1.58-1.71),LEA风险HR 1.85(95%CI 1.32-2.61)。
  • 高危患者中各ICI类别PAD风险:PD-1抑制剂HR 1.64(95%CI 1.57-1.71),PD-L1抑制剂HR 1.64(95%CI 1.51-1.78),CTLA-4抑制剂HR 1.82(95%CI 1.60-2.06)。

临床怎么用

  • 对接受ICI治疗的癌症患者,尤其合并高血压、高脂血症、糖尿病或吸烟史者,应加强血管评估与PAD监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy and improved survival across multiple malignancies. Although associations with cardiovascular events have been described, the relationship between ICIs and peripheral artery disease (PAD) remains unclear. The study aimed to determine whether ICI treatment is associated with PAD, chronic limb-threatening ischemia (CLTI), or lower extremity amputation (LEA) in patients with cancer. METHODS: We conducted a retrospective multicenter cohort study using the TriNetX Analytics platform to identify cancer patients treated with ICIs or non-ICI therapies between 2005 and 2025. Propensity score matching (1:1) was performed to balance baseline characteristics. Outcomes included PAD, CLTI, LEA within five years. Kaplan-Meier analyses assessed survival probabilities, and hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated using Cox models. Subgroup analyses evaluated outcomes across different ICI classes and within at-risk groups with hypertension, hyperlipidemia, diabetes, or smoking history. RESULTS: The matched cohort included 66,766 patients treated with ICIs and 66,766 controls. Kaplan-Meier analysis showed a lower 5-year PAD-free survival in the ICI group (73.6% vs 81.7%; P < .001). On multivariable analysis, although the risks of CLTI and LEA were similar, ICI treatment was associated with increased risk of PAD (HR, 1.59; 95% CI, 1.53-1.64). Consistently, an increased risk of PAD was demonstrated across all ICI classes: programmed cell death protein-1 inhibitors (HR, 1.56; 95% CI, 1.47-1.55), programmed cell death ligand-1 inhibitors (HR, 1.48; 95% CI, 1.36-1.61), and cytotoxic T-lymphocyte associated protein 4 (cytotoxic T-lymphocyte-associated antigen-4) inhibitors (HR, 1.58; 95% CI, 1.43-1.74). Among at-risk patients (n = 27,932), Kaplan-Meier analysis showed a lower 5-year PAD-free survival in the ICI group (70.3% vs 80.2%; P < .001) and ICI treatment was associated with an increased risk of PAD (HR, 1.64; 95% CI, 1.58-1.71) and LEA (HR, 1.85; 95% CI, 1.32-2.61). Furthermore, a higher risk of PAD was demonstrated across each ICI class among at-risk patients: programmed cell death protein-1 inhibitors (HR, 1.64; 95% CI, 1.57-1.71), programmed death ligand-1 inhibitors (HR, 1.64; 95% CI, 1.51-1.78), and CTLA-4 inhibitors (HR, 1.82; 95% CI, 1.60-2.06). CONCLUSIONS: In this multicenter cohort of adults with cancer, ICI therapy appears to be associated with increased risks of PAD and LEA, particularly among individuals with preexisting vascular risk factors. These findings suggest that ICI may contribute to PAD and highlight the need for vascular assessment and monitoring in patients receiving ICIs.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Chwa JS, Hong AT, Lin F, et al. Immune checkpoint inhibitors are associated with peripheral artery disease in cancer patients. J Vasc Surg. 2026. PMID: 41687935. doi:10.1016/j.jvs.2026.02.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。